English

Interim report January - September 2020: Good profitability and continued recovery

Report this content

Third quarter:

  • Sales amounted to SEK 320 (378) million, corresponding to a decrease of 15 percent in SEK. Sales decreased by 11 percent in local currency. Sales were negatively impacted by Covid-19 as a result of reduced demand. During the third quarter the recovery in demand continued, even though the rate of recovery varied between divisions and market regions.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 134 (155) million, corresponding to a margin of 42 (41) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 9 million.
  • Net income amounted to SEK 89 (107) million, which gave earnings per share of SEK 0.81 (0.98).

January – September:

  • Sales amounted to SEK 863 (1 071) million, corresponding to a decrease of 19 percent in SEK. Sales decreased by 19 percent in local currency. Sales were negatively impacted by Covid-19 as a result of reduced demand.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 290 (428) million, corresponding to a margin of 34 (40) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 3 million.
  • Net income amounted to SEK 180 (287) million, which gave earnings per share of SEK 1.65 (2.64).

Gothenburg, November 6, 2020
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on November 6, 2020.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Subscribe

Documents & Links